Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INN-03-02
- Development stage
- Preclinical
- Lead developer
- Innox Pharma
- Modality
- Small Molecules
01
Overview
INN-03-02 is an investigational small molecule drug candidate being developed by Innox Pharma for the treatment of solid tumors. It belongs to the INN-03 development program, which focuses on broad-spectrum kinase inhibitors, specifically those targeting Class III kinases and FLT3/ITD. While the parent compound INN-03 is described as a kinase inhibitor, INN-03-02 is a specific iteration currently in clinical-stage development for oncology indications. Detailed information regarding its specific molecular targets and the exact phase of clinical trials has not been publicly disclosed in the company's high-level pipeline summaries.
Beyond the preview
Go deeper on INN-03-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INN-03-02.